Suomen Solubiologit ry

Yhdistys edistää solubiologian tutkimusta, koulutusta, tiedotusta ja työpaikkojen perustamista solubiologeille harjoittaen koulutus- ja tiedotustoimintaa.

Liity jäseneksi

Ajankohtaista

Laboratory technician – Nightingale Health Oy, Helsinki

16.6.2018 | Ajankohtaista

Laboratory technician – Nightingale Health Oy, Helsinki

Are you passionate about healthcare and public health research? Do you want to work in a state of the art laboratory with cutting edge analytical technology?

Nightingale Health is looking for a laboratory technician to join our delivery team. Our delivery team serves global customers, using NMR spectroscopy to deliver analytical measurements for population health research and clinical use.

We’re looking for an enthusiastic and dependable laboratory technician with some prior knowledge of analytical measurements and work experience in a clinical laboratory. Previous experience of NMR spectroscopy or automated liquid handlers is not required but is considered an asset.

We are looking for people with:

– Trained laboratory technician or medical laboratory scientist (or equivalent) passionate about utilizing the latest measurement techniques, especially nuclear magnetic resonance (NMR) spectroscopy
– A ”quality first” mind-set
– Work experience with analytical measurements
– Willingness to adapt to a flexible team culture and learn novel measurement technologies
– Strong knowledge of the English language, Finnish is a plus but not mandatory

We offer:

– Responsibility and independence as a member of the delivery team
– Unique opportunity to work in a multidisciplinary team of scientists, developers and biotech business professionals
– Full-time position in our laboratory in Helsinki or Kuopio
– Attractive employment conditions and competitive salary

The position is available immediately or upon agreement.

How to apply?

If you are interested in joining our rapidly growing team, please send your application to people@nightingalehealth.com. The applications should include a cover letter and CV. The applications may be submitted in Finnish or in English.

Sales Representative – SOPHiA GENETICS, Finlande

16.6.2018 | Ajankohtaista

Sales Representative – SOPHiA GENETICS, Finlande

Job description

Ranked among the ”50 Smartest Companies” in the world according to the MIT Technology Review SOPHiA GENETICS is a fast-paced rapidly growing health tech company with a team of world renowned experts in the fields of technology (AI), life sciences (genomics) and information technology (data security) sectors.

SOPHiA GENETICS has developed SOPHiA™ Artificial Intelligence, the most advanced and used technology for clinical genomics. Deployed as a Software as a Service SOPHiA DDM® has connected over 425 world-leading hospitals and analyses thousands of patients’ genomics profiles each month to better and faster diagnose them.

In our mission to democratize Data-Driven Medicine, we are looking for bright, passionate and dedicated individuals to join our growing dynamic team. Does this sound like you? If so, we want to hear from you…

Sales & Business Development Manager

As part of the sales team, you will be in charge to acquire new accounts as well as managing existing ones within your territory (Finland, Estonia, Latvia, Lithuania) for our portfolio. This position requires to intensely travel across your territory as well as in Switzerland twice per year where is based our headquarter.

You will have to be creative and find solutions in order to meet clients. You will be supported by a well-resourced team of technical specialists and will leverage on our network within the clinical diagnostic testing field. The ability to develop long-term relationships with clients and communicate your enthusiasm for the potential of use of our solution transition to data-driven personalized medicine is essential. Our teams will support you in achieving ambitious goals in terms of acquisition of new clients and sales by sharing with you best practices. If you are client oriented and a result person you might probably join our team.

Qualifications and Experience

  • A master degree in Sciences within a well-regarded institution; PhD will be an advantage.
  • Excellent communication skills, including experience in communicating complex scientific principles in simple terms.
  • Finnish and English (the business language) is mandatory.
  • Ideally, previous experience as working as part of a team to develop the company’s customer base and provide a first-class experience to clients, preferably in the clinical diagnostics, biotechnology or medical technology market.

Starting date: ASAP
Location: Home office
If you think you fit this position, please send a CV and a cover letter.
Please note that incomplete applications will not be considered.

Clinical Research Associate / Study Manager – PerkinElmer, Inc. Turku, VARS

16.6.2018 | Ajankohtaista

Clinical Research Associate / Study Manager – PerkinElmer, Inc. Turku, VARS

Job description

PerkinElmer is currently looking for
Clinical Research Associate / Study Manager
Turku, Finland / Diagnostics

The Turku Site, with 550 employees, represents one of PerkinElmer’s major manufacturing and product development sites for newborn- and maternal fetal health screening. As the global market leader in newborn screening, our solutions have tested over 560 million babies worldwide for life-threatening diseases.

Medical and Scientific Affairs organization is responsible for clinical validation of our products. We now are looking for a new colleague to our global MSA team. The position may also be located in Sollentuna where PerkinElmer has a center of excellence for research and development of molecular diagnostic products.

Role description:

    • Plan, execute and report studies according to applicable regulatory requirements and company SOPs
    • Prepare study protocols and start-up activities at study sites
    • Obtain ethical and regulatory approvals
    • Monitor studies and report results
    • Coordinate studies and develop internal clinical study management procedures
    • Work in close collaboration with different functions and stakeholders including R&D, Regulatory and Business

Role requirements:

    • M.Sc or equivalent in bioscience
    • Experience in clinical studies, preferably related to In Vitro Diagnostic or Medical Device products
    • Excellent organizational and communication skills
    • Ability to work independently
    • Proven ability to work in global team environment
    • Fluent Finnish or Swedish and English (spoken and written)
    • Ability to travel up to 30 days per year, mainly in Europe
    • Depending on your previous experience with IVD clinical studies the position may be either Clinical Research Associate or Clinical Study Manager.

What we offer:

    • Opportunity to work in a global team
    • Dynamic and innovative culture
    • Focus on career development
    • Collaborative and diverse environment

In this position, you will be reporting to the Leader of Global Clinical Affairs, Turku. The position is temporary, approximately for 1 year, and can be located in Turku, Finland or Sollentuna, Sweden.

This position provides an exciting opportunity to work in a highly international business environment. If you are interested in the position and feel that you have the necessary skills and experience, please fill your application by June 25th, 2018. We will review the applications on an ongoing basis.

The PerkinElmer Turku Site is a drug free site and a medical examination for new employees includes a drug test.

Solubiologi-lehti

16.6.2018

Solubiologi 1/2018

Pääkirjoitus, 28.05.2018

Suomen kesä on alkanut erittäin lämpimästi ja kesän tuloon liittyy tietysti myös vuoden ensimmäinen Solubiologi. Tämän vuotisen kevään numeron aloittaa Marjaana Parikainen, joka avartaa meille kollageeni I:stä sitovan α2β1-integriinin roolia eturauhassyövässä, ja tämän vaikutusta geeniekspressioon ja invaasioon. Seuraavaksi Teemu Syrjälä kertoo meille brominoituneista palonestoaineista ja niiden vaikutuksista syöttösoluihin. Tämänkertaisen tietopaketin päättää Moona Huttusen ulkomaankirjeenvaihtotervehdys, jossa käydään läpi hänen jo kolme vuotta kestäneitä seikkailuitaan Lontoossa University Collegessa, Englannissa.

Tänä kesänä saimme mahdollisuuden lähteä laboratorioryhmän kanssa joukolla Suomea pakoon vierailulle TuE:hen (Technische Universiteit Eindhoven) Eindhoveniin, Hollantiin, jossa tapasimme ryhmänjohtajamme Cecilia Sahlgrenin toisen ryhmän tiimiläisiä. Ahkerana professorina Cecilia pyörittää siis kahta kokonaisuutta, ja olihan se mielenkiintoista päästä tutustumaan teknillisen yliopiston työtapoihin ja tekniikkoihin. Tämä alunperin 1956 perustettu yliopisto kouluttaa pääasiassa insinöörejä teknologian alalla, mutta solu- ja kudostekniikan ja mikrofabrikoinnin laboratoriot yhdistävät solubiologiaa ja biotekniikkaa. Yhteistyö insinöörien ja solubiologien välillä on tärkeässä asemassa TuE:ssa, kun kehitetään esimerkiksi keinotekoisia sydänläppiä tai mikrosiruja, joilla halutaan simuloida erilaisia olosuhteita, joihin solut voivat joutua. Lopullisena päämääränä on kehittää niin sanottuja organ-on-a-chip –menetelmiä, joilla voitaisiin simuloida kokonaisia elimiä pienoismallissa.

Tämä jäänee omalta osaltani päätoimittajuuteni viimeiseksi Solubiologi-lehdeksi, koska syksyllä puikkoihin tarttuu J.J. Hyvää kesän jatkoa kaikille toivottaa SEb ja koko Solubiologin väki.

– Sebastian Landor

”I am the easy-going doctor who does not need to salute properly. You will find that I am always removing my gloves. The reason for my lab coat being a slightly different color to yours is never explained.”

 

1. Artikkeli. Kollageenireseptori α2-integriini säätelee eturauhassyöpäsolujen geeniekspressiota ja invaasiota, Marjaana Parikainen (FM)

Erikoistyössä tutkittiin α2-integriinin vaikutusta eturauhassyöpäsolujen geeniekspressioon sekä solujen migraatioon ja invaasioon neljällä α2-integriiniä erilaisesti ilmentävällä DU145-solutyypillä. α2-integriinin havaittiin säätelevän tiettyjen geenien ilmentymistä sekä RNA- että proteiinitasolla mutta se ei vaikuttanut säätelemiensä proteiinien lokalisaatioon solussa. Lisäksi havaittiin, että α2β1-kollageeni I -vuorovaikutus lisäsi solutyyppien välisiä RNA-tason ilmentymiseroja suurimmalla osalla tutkituista 12 geenistä, minkä perusteella α2-integriinin aktivoituminen ja signalointi ligandivuorovaikutuksessa säätelee näiden geenien ilmentymistä. α2-integriiniä ilmentävät solut invasoivat enemmän Matrigeeliin ja kollageeni I:een kuin α2-integriiniä ilmentämättömät solut. Tulosten perusteella α2β1-integriiniin kohdentuvaa syöpähoitoa voitaisiin mahdollisesti hyödyntää eturauhassyövän luumetastaasien estämiseen.

 

2. Artikkeli. The effects of some common brominated flame retardants (bfrs) on cell degranulation and cell viability in a mast cell line, Teemu Syrjälä (Biomedical Laboratory Scientist, Bachelor of Health Care; EQF6)

The aim of this study was to investigate the effects of two commonly used brominated flame retardants, tetrabromobisphenol A (TBBPA) and hexabromocyclododecane (HBCD), on degranulation and viability of a mast cell line RBL-2H3. Assays measuring and monitoring cell viability and the release of inflammatory proteins via degranulation were developed. The results showed that both TBBPA and HBCD cause substantial cell death over a long-term exposure in vitro. Both compounds caused some degranulation of the cells, although the results from HBCD turned out to be quite modest compared to those gotten from TBBPA. TBBPA greatly induced cell death by apoptosis while only a very small degree of necrotic cell death was observed. While the degree of necrosis caused by HBCD remains unknown, it was shown to also induce apoptotic cell death at least to some extent. The study concludes that TBBPA, based on the results, does seem to be a mast cell sensitizing agent. HBCD has great potential to have similar effects, although this requires further research.

 

3. Artikkeli. Ulkomaankirjeenvaihtaja, London University College (UCL) Englanti, Moona Huttunen (FT)